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Abstract
Although EML4-ALK transforming fusion gene is represented in only 8% of non-small cell lung
cancer (NSCLC) cases, its expression is partly responsive for the failure of current NSCLC
treatments. Preventing secondary mutation of the ALK protein through direct gene manipulation
could overcome NSCLC drug resistance.
Method: In this study, we developed a gold nanoshell (HAuNs) drug carrier for delivery and
selective photo-thermal release of genes that target ALK and microRNA-301 in NSCLC.
Additionally, the densely-coated nanoshell adsorbed high amounts of the positively-charged
anticancer drug doxorubicin (DOX), generating an exciting multidimensional treatment strategy
that includes gene-, thermal- and chemo- therapy.
Results: The ALK mRNA and microRNA-301 genes as the double targets exhibited the combined
effect. The drug carrier system significantly improved the drug accumulation in tumor tissues due to
the enhanced vascular permeability by photothermal effect, dense spherical structure and RGD
peptide modification.
In vitro and in vivo results demonstrated the multiple therapeutic effects of the gold nanoshell-based
system was better than the monotherapy.
Conclusion: The above results indicated the gold nanoshell-based system would be a promising
translational nano-formulation platform for effective treatment of EML4-ALK-positive NSCLC.
Key words: EML4-ALK, gold nanoshell, gene therapy, hyperthermia, chemo-therapy.

Introduction
Lung cancer is the first leading cause of death
among different cancer types. In the past 10 years, the
morbidity and mortality of lung cancer worldwide
has continued to increase, clearly becoming a major
threat to public health [1]. Each year, about 1.5 million
new cases of lung cancer are reported, and 80 % of
these cases are diagnosed as non-small cell lung
cancer (NSCLC) [2]. Among the different kinds of
NSCLC,
those
expressing
the
echinoderm
microtubule-associated
protein-like
4-anaplastic
lymphoma kinase (EML4-ALK) fusion gene mutation
are among the most malignant types [3].

Approximately 8% of NSCLC patients are EML4-ALK
positive, and it is estimated that approximately 70,000
new cases of EML4-ALK gene-positive lung cancer
will occur all over the world in one year. [4].
EML4-ALK mutations show a strong
exclusiveness in NSCLC patients, which means this
kind of mutation occurs alone without mutations of
other driving genes. For example, EML4-ALK fusion
gene scarcely coexists with EGFR and other
mutations. As a result, in the NSCLC patients
expressing EML4-ALK mutations, treatment with
EGFR-targeted inhibitors was associated with a poor
http://www.thno.org
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prognosis. Consequently, EML4-ALK fusion gene has
become a unique therapeutic target for the 8% of
NSCLC patients expressing EML4-ALK mutations,
with great clinical significance [5]. The ALK-targeted
small molecule drug crizotinib and its derivatives
have shown encouraging results in the initial
treatment of ALK-positive NSCLC patients. However,
these ALK-targeted drugs have been shown to induce
mutations of ALK kinase and increase ALK gene copy
number with continuous treatment, resulting in the
occurrence of drug resistance [6]. Patients treated with
crizotinib or crizotinib-based drugs showed acquired
drug resistance to different extents after 8 months,
leading to tumor recurrence [6-8]. Gene therapy for
target proteins can be an effective strategy for
suppressing protein expression and can significantly
improve therapeutic efficacy. Moreover, gene therapy
may prevent the occurrence of secondary drug
resistance caused by drug-induced mutations [9,10].
Gene therapy inhibits the expression of target
proteins by suppressing the mRNA of the target
protein. Small interfering RNA (siRNA) is a
promising strategy to inhibit the target ALK mRNA
for cancer therapy [11-13]. Takezawa et al. reported
that the over-expression of ALK protein could activate
both JAK/STAT3 and RAS/ERK signaling pathways
to enhance expression of the anti-apoptosis gene
Survivin and inhibit the tumor suppressor gene Bim,
promoting the development of tumor cells in the
EML4-ALK fusion mutant NSCLC [14]. Accordingly,
down-regulation of ALK mRNA expression could
increase the expression of Bim to induce tumor cell
apoptosis. However, inhibiting ALK mRNA alone
could hardly achieve an ideal therapeutic effect
because intracellular protein expression is a complex
process that is regulated by cross-effects of multiple
signaling pathways [15]. Recently, researchers have
paid much attention to the study of microRNA’s
function. A recent study showed that miR-301a is
involved in PC progression. Lee et al. investigated
aberrant miRNA expression in PC, and showed
increased levels of miR-301a in PC tissues [16]. Lu et
al.
certified
that
miR-301a
downregulated
NF-kB-repressing factor (Nkrf) and elevated NF-kB
activation [17]. Chen et al. revealed that the presence
of microRNA-301 in pancreatic cancer cells
down-regulates Bim expression, thereby promoting
the proliferation of tumor cells [18,19]. Hence, we
selected microRNA-301 as another target to amplify
the treatment outcome.
In gene therapy, a specific strategy for gene
transfection is indispensable to introduce foreign
genes into target cells. Gold nanoshell is a novel type
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of biocompatible nano-carrier, which is currently
under investigation as a hyperthermia agent for
cancer treatment in a phase II clinical trial [20]. The
large surface area of gold nanoshell presents the
opportunity to upload multiple genes and drugs
simultaneously to improve therapy. The unique
spatial structure formed by the densely coated
spheroidal particles can prevent the biomolecules
from being rapidly degraded by enzymes in the blood
circulation [21-23]. Combined with the good
optical-to-thermal conversion efficiency of gold
nanoshell, increased temperature can break the
thiol-Au bond upon NIR light irradiation, which can
trigger subsequent release of the siRNAs and
chemotherapeutic agents for controlled therapy
[24-31]. In addition, the photothermal effect could
enhance local blood perfusion and vascular
permeability in tumors, resulting in improved
accumulation and penetration of the gold
nano-system into the tumor microenvironment [32].
Simultaneously, the surface of the gold nanoshell can
be
modified
with
tumor-targeting
ligands,
transforming the nano-carrier into a tumor-avid
nanoparticle [33-37]. Furthermore, the dense spherical
structure of the gold nano-system may facilitate its
cellar uptake [38]. With the active targeting ligand
RGD peptide and its dense spheroidal structure, a
high concentration of HAuNs accumulated in cancer
cells. Interestingly, we found that nanoshells densely
coated with siRNA could absorb more of the
positively charged anticancer drug doxorubicin
(DOX),
allowing
for
combinatory
therapy.
Concurrently, the heat caused by NIR irradiation on
the gold nanoparticles could damage the tumor tissue
and cells at a macroscopic level, while the gene- and
chemo-therapy could inhibit the cells in a molecular
level. Therefore, the treatment should exhibit a
synergistic effect with the combination of gene
therapy, chemotherapy and hyperthermia therapy.
Herein, we established a drug delivery system
based on the gold nanoshell DOX@siRNA@HAuNs to
explore an alternative effective treatment paradigm
for EML4-ALK fusion mutant NSCLC. Inhibition of
ALK and miR-301 exhibited a synergistic apoptotic
effect on EML4-ALK cells. The drug carrier system,
DOX@siRNA@HAuNs, showed many remarkable
abilities, such as high drug-loading capacity, siRNA
sequence protection, and tumor targeting ability. The
amplified synergistic therapeutic effect was
demonstrated both in vitro and in vivo, indicating the
DOX@siRNA@HAuNs drug carrier system is a
promising nanoplatform for EML4-ALK NSCLC
treatment.

http://www.thno.org
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Materials and methods

Nucleic acid electrophoresis assay of siRNA
protection

Materials

To investigate the protective effect of
siRNA@HAuNs, delivery vectors were incubated
with 0.25% RNase A for 0.5 h. Then, the sample was
loaded on a 1% agarose gel containing 0.01% Gel-Red
and run at 90 V for 30 min. To release the loaded
siRNA, the samples were treated with heparin at a
dose of 1 U/mg siRNA in DEPC-treated water.

Cobalt chloride hexahydrate, chloroauric acid
(HAuCl4), trisodium citrate dehydrate, and sodium
borohydride were purchased from Guoyao Reagent
Corporation (Shanghai, China). Dithiothreitol (DTT)
and glutathione (GSH) were purchased from
Sigma-Aldrich Inc. (USA). Sulfhydryl polyethylene
glycol, and RGD peptide were purchased from
Shanghai Sangon Biotech, Inc. EML4-ALK mutation
cells H2228, normal liver cells L02 and NSCLC A549
(ALK fusion-negative, as control cells) cells were
obtained from KeyGen Biotech. (Nanjing, China).
Athymic nude mice were purchased from SLAC
Laboratory Animal Co. Ltd. (Shanghai, China).
Bovine serum albumin and cell culture media were
purchased from Sangon Biotech (Shanghai) Co., Ltd.
The siRNAs and nonsense sequences with or without
the modification of -SH and FITC were purchased
from Sangon Biological Engineering Technology &
Co. Ltd. (Shanghai, China).

Synthesis of RGD @siRNA@HAuNs drug
delivery system
Hollow gold nanoshells (HAuNs) were prepared
by the previously reported method [23]. Stable
suspensions of silver nanoparticles were synthesized
in minutes using an aqueous solution of sodium
citrate and silver nitrate, and the addition of sodium
borohydride accelerated the chemical reaction. The
reaction proceeded at 60 °C. Larger silver particles
were formed from these nanoparticles by reducing
additional silver nitrate in the presence of
hydroxylamine hydrochloride; the nanoparticles act
as nuclei for further growth. Then, the silver
nanoparticles were converted into hollow gold
nanoshells (HAuNs) by adding HAuCl4 directly to the
as-grown nanoparticle solution. Subsequently,
multiple copies of siRNA were conjugated to the
surface of the HAuNs either directly or supported by
a single strand DNA linker through a quasi-covalent
(Au−S) bond. Finally, moderate DOX accumulated on
the surface of the prepared siRNA@HAuNs by
electrostatic adsorption, forming the DOX@siRNA@
HAuNs drug delivery system. The nanoparticles were
stored at 4 ℃. For the fabrication of the combinatory
drug delivery system, Thiol-PEG-COOH was used as
a stabilizer as well as a linker/spacer to attach various
agents to HAuNs via one end of the thiol group. The
amino group of the targeting peptide RGD was
coupled with the carboxyl group of thiol-PEG-COOH
(amount ratio RGD/PEG=1:1) through EDC reaction
catalyzed by NHS.

Endosomal escape of siRNA
Approximately 3×105 H2228 cells were seeded
onto confocal dishes and incubated overnight at 37 °C.
Cells were then treated with siRNA@HAuNs (siRNA
with FITC). After incubation for 4 h, Lyso-Tracker Red
was added and incubated for 0.5 h. Then, the
intracellular fluorescence was visualized using
confocal laser scanning microscopy (CLSM).

Laser-induced DOX release
Approximately 3×105 H2228 cells were seeded
onto confocal dishes and incubated overnight at 37 °C.
Cells were then treated with RGD@DOX@HAuNs
(siRNA without FITC) and imaged before or after
laser treatment (785 nm light irradiation, 1.2 W/cm2,
for 5 min). After incubation for 4 h, Hochest was
added and incubated for 0.5 h. Then, the intracellular
fluorescence was visualized using CLSM.

In vitro therapeutic effect
Cellular toxicity of nanoshells and the
DOX@siRNA@HAuNs drug delivery system in
different cell lines and conditions was measured by
MTT assay. Cell apoptosis caused by the
DOX@siRNA@HAuNs drug delivery system with 785
nm laser was detected by flow cytometry and LCSM.

In vivo therapeutic efficacy
All animal experiments were carried out in
compliance with the Animal Management Rules of
the Ministry of Health of the People's Republic of
China (document NO. 55, 2001) and the guidelines for
the Care and Use of Laboratory Animals of China
Pharmaceutical University. Nude mice bearing
H2228-derived tumors were randomly assigned to 1
control group and 5 experimental groups (n=5) when
the tumor diameter reached 0.5 cm. Mice in the
control group were injected with PBS while the
experimental groups were injected with DOX, bare
nanoshells and DOX@siRNA@HAuNs. 12 h
post-injection, different therapeutic schedules were
performed on each experimental group: (1) Dox
injection without light irradiation; (2) 785 nm light
irradiation (1.2 W/cm2) for 5 min with nanoshell
injection; (3) 785 nm light irradiation (1.2 W/cm2) for 5
http://www.thno.org
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min with DOX@siRNA@HAuNs. Tumor sizes and
body weights were measured every other day. Tumor
volumes were measured using calipers and calculated
according to the following formula: size (mm3) =
length (mm) × width (mm)2/2. All mice were
sacrificed and the tumors were collected 14 days after
treatment.

(25.7%) or microRNA-301 (25.1%) alone (Figure
1D-E). The ensemble of these results lends strong
support to the development of a dual gene targeting
strategy for treating EML4-ALK NSCLC.

Results and discussion

The structure of RGD@siRNA@DOX@HAuNs
and the mechanism of target selection are illustrated
in Scheme 1. The transmission electron microscopy
(TEM) image of the prepared RGD@siRNA@DOX@
HAuNs (Figure 2A) shows a core-shell structure of
the drug carriers. The mean hydrated diameters of the
nanoshell and the sequence-coated shell are ~25 nm
and ~35 nm, respectively (Figure S1A-B) and the PDI
value was ~0.06. Analysis of the photothermal
conversion showed that laser irradiation can quickly
and significantly increase the temperature from 25 °C
to ~53 °C within 5 min (Figure 2B).
The UV-visible absorption spectra of various
components (Figure S1C) confirmed the successful
conjugation of siRNA (absorption peak @215 nm),
DOX (absorption peak @480 nm), and HAuNs
(absorption peak @800 nm), with a Zeta potential of
-13 mV for HAuNs (Figure S1D). Modification of the
positively charged RGD peptide slightly changed the
Zeta potential to -12 mV. In particular, uploading the
negatively charged siRNA greatly enhanced the
negative potential (-20 mV), favoring enhanced
adsorption of the positively charged anticancer drug
DOX. The siRNA was loaded onto the HAuNs by
Au-S bonds, not by electrostatic adsorption, so the
negative potential would not hinder uploading of
siRNA in this study. The fluctuation in Zeta potential
indicates the success of each reaction process and
production of the novel drug delivery system
RGD@siRNA@DOX@HAuNs.
The correlation of siRNA loading with DOX
adsorption was also investigated. We found that
nanoshells with increased coating of negative siRNA
sequence (siRNA@ HAuNs) could adsorb more DOX,
with a maximum of 20% DOX loading (the amount of
DOX was calculated by the ultraviolet absorption
spectrum of DOX in the solution). At low
concentrations, there was a linear relationship
between the loading quantities of siRNA and DOX.
Specifically, we found that the optimal siRNA loading
concentration to achieve 20% of DOX loading was 200
nM (Figure 2C). The laser-triggered release of
RGD@DOX@siRNA@HAuNs as a whole was
analyzed at different illumination times (Figure 2D).
Within 5 min of laser light exposure, there was a
linear relationship between laser duration (minutes)
and cumulative drug release (%). In addition, a 5 min

Function of ALK siRNA and miRNA-301
inhibitor in H2228 cells
We used western blot to confirm the function of
the double gene therapy targeting ALK and
miRNA-301 in H2228 cells. Treatment of the cells with
ALK siRNA significantly down-regulated the
expression of ALK and the phosphorylation level of
downstream protein p-ERK in H2228 cells, inhibiting
cell proliferation (Figure 1A). In addition, ALK siRNA
increased the expression of apoptotic protein Bim. The
results also showed that the miRNA 301 inhibitor
improved Bim expression, while miRNA 301 mimics
suppressed Bim activity in H2228 cells. Interestingly,
the ALK siRNA treatment had little or no influence on
Bim expression in A549 cells where the ALK level was
in the normal range (Figure 1B). These results indicate
that the effect of ALK siRNA is cell-dependent and
the ALK siRNA-based treatment would be specific. In
addition, both ALK siRNA and miRNA 301a inhibitor
are able to increase the expression of Bim in H2228
cells. Therefore, simultaneous inhibition of the
dual-targets, ALK mRNA and miRNA 301a, could
exert a synergistic effect on the survival of EML4-ALK
fusion mutation lung cancer. We compared the cell
viability of EML4-ALK mutation H2228 cells and ALK
fusion-negative A549 cells after siRNA transfection
with Lipofectamine (Figure 1C). We found that the
cell viability of H2228 cells (33.1%) was much lower
than that of A549 (81.3%) when the cells were
incubated together with ALK siRNA and
microRNA-301 (p<0.05). This finding suggests that
the double target gene therapy amplified its
therapeutic effect in cancer cells. The fact that the
normal NSCLC A549 cells survived over 80% in each
group indicates that this combination therapy is
selective to cancer cells expressing higher levels of
EML4-ALK mutation than ALK fusion-negative cells.
We next postulated that apoptosis induction
may mediate the cytotoxic effect of the combination
therapy. To test this hypothesis, the extent of cell
apoptosis following different treatments was
analyzed using flow cytometry (FCM). After
simultaneously transfecting cells with both siRNAs,
the apoptosis rate of H2228 cells increased to 44.1%,
which was higher than the effects of ALK siRNA

Synthesis and Characterization of
RGD@siRNA@DOX@HAuNs drug delivery
system

http://www.thno.org
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light exposure was sufficient to trigger the release of
over 80% of siRNA and DOX, indicating that drug
release from the HAuNs drug carrier could be
controlled by light illumination.
The stability and drug release properties of
HAuNs before and after PEG coupling were
characterized at different pH values and different
concentrations of salt solution (Figure S2A-D). The
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results show that the cumulative drug release of both
siRNA and DOX were low under different conditions,
with the exception of DOX release in acidic
environments. This unique property might enhance
drug release in the tumor microenvironment, which is
known to be more acidic than surrounding tissue (pH
value : blood and healthy lung tissue 7.35~7.45; tumor
lung tissue 6.5~7.0).

Figure 1. The mechanism of treatment target selection and the synergistic effect of gene silencing. (A) Western blot assay after ALK siRNA, miR-301
inhibitor and miR-301 mimics transfection in H2228 cells. (B) Western blot assay after ALK siRNA transfection in A549 cells. (C) Survival of cells treated under the
conditions in (A-B) determined by MTT assay. (D) Apoptosis of cells treated under the above conditions assayed by AV-PI kit. (E) Quantitative analysis of (D). Data
are given as mean ± SD (n=5). *, P<0.05.

http://www.thno.org
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Scheme 1. Schematic illustration of the nanostructure design and the target selection mechanism of gene therapy.

Figure 2. Characterization of the RGD@siRNA@DOX@HAuNs drug carrier system. (A) Transmission electron microscopy (TEM) characterization of
the drug carrier system. (B) The photothermal conversion of HAuNs with NIR laser irradiation (C) Relationship between the amount of conjugated siRNA and DOX
adsorption (siRNA-FITC: 520 nm, DOX: 585 nm). (D) Relationship between drug release and light irradiation time (siRNA-FITC: 520 nm, DOX: 585 nm). Data are
given as mean ± SD (n=5). *, P<0.05.

http://www.thno.org
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Properties of the RGD@DOX@siRNA@
HAuNs drug delivery system
siRNA sequence protection ability
The nucleic acid electrophore diagram (Figure
3A) depicts the stability of siRNA in a solution of the
hydrolytic enzyme (Rnase 1). siRNA and siRNA@
HAuNs exhibited bright spots in the electrophore lane
(lane a\b) without Rnase 1 incubation. When ALK
siRNA itself was incubated with Rnase 1, no signal
was detected in the lane, implying complete
degradation of the siRNA. However, upon
attachment of ALK siRNA to the HAuNs, a bright
signal was observed in the Rnase 1 and serum
solution, indicating that the nanoshell protected the
coated siRNA. As expected, the siRNA sequence was
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detached from the shell after NIR irradiation and
degraded by the Rnas I enzyme, leading to
disappearance of the signal in the electrophore lane.
These results support the siRNA protective ability of
the HAuNs carrier.

Improved transfection efficiency
Figure 3B shows a comparison of the gene
transfection efficiency of HAuNs and the widely used
commercial Lipofectamine reagent Lip2000. After
incubation with siRNA@HAuNs, the expression of
ALK in H2228 cells was significantly suppressed
(28.8%), while it remained at 41.2% with Lip2000
transfection (p<0.05). The results indicated that
HAuNs are an ideal siRNA vector with better gene
transfection efficiency than Lipofectamine.

Figure 3. The properties of the RGD@siRNA@DOX@HAuNs drug carrier system. (A) The nucleic acid electrophore diagram for various conditions.
(B) Relative mRNA expression of EML4-ALK determined by real-time PCR. (C) Laser confocal microscopy image of endosomal escape of
RGD@siRNA@DOX@HAuNs before and after laser illumination; red: lysosome, green: siRNA-FITC, and yellow: colocalization of siRNA -FITC and endolysosome.
(D) Laser confocal microscopy image of DOX release after laser illumination; red: DOX, blue: hochest. Data are given as mean ± SD (n=5). *, P<0.05.

http://www.thno.org

Theranostics 2018, Vol. 8, Issue 10
Endosomal escape
The localization of siRNA@HAuNs in H2228
cells was imaged by confocal microscopy (Figure 3C).
Before NIR irradiation, the siRNA@HAuNs (green
fluorescence) were well colocalized with endosomes
(red fluorescence), indicating that siRNA@HAuNs are
in the endosomal compartment. However, after NIR
irradiation, the green fluorescence separated from the
red, suggesting that siRNA@HAuNs escaped from
the endosome, supporting the endosomal escape
ability of HAuNs with laser-induced heat generation.
It is known that nanoparticles may initially enter the
endosome after cell uptake and then be transferred to
the lysosome, where the particles and loaded drugs
are degraded. To avoid this fate, the nano-carriers
should be designed to quickly escape from lysosomes
to allow the effective drug to reach the target. For this
nanoshell-based drug system, NIR irradiation
induced photothermal effects, leading to permeabilization of endosomes by the increased temperature.

DOX release
To further explore the control of DOX release
from the drug delivery system, DOX@siRNA@
HAuNs were irradiated at the cellular level using a
laser confocal microscope (Figure 3D). DOX and
nuclear dye fluorescence were false-colored red and
blue, respectively. The result shows that the red and
blue fluorescence did not overlap without irradiation,
indicating that DOX did not enter the nucleus because
most DOX was adsorbed onto DOX@siRNA@HAuNs.
However, after light treatment, drug release was
evidenced by red and blue fluorescence overlap,
showing that a large amount of DOX was released
from DOX@siRNA@HAuNs and entered the nucleus.
These results also confirmed that DOX release can be
achieved by 785 nm laser irradiation. The reason that
DOX could be released by laser irradiation is mainly
by the breakage of siRNA from HAuNs (Au-S) and
HAuN collapse, which leads to a change in electric
potential [25,26].

Tumor-targeting ability of the
RGD@DOX@siRNA@HAuNs drug delivery
system
Figure 4A compares the cellular uptake of the
nanoshell system with and without RGD modification. RGD peptide conjugation was found to
significantly improve the efficiency of drug uptake by
H2228 cells. At a similar incubation time (30 min), the
RGD-modified group showed stronger green
fluorescence (FITC-labelled siRNA) than the
non-RGD group. Quantitative analysis of HAuNsassociated fluorescence intensities demonstrated that
the RGD conjugation significantly increased (p<0.05)
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the cellar uptake of the drug delivery system (more
than double growth) (Figure 4B). For further
evaluating the cellar uptake of gold nanoparticles
coated with different components, dark field
microscopy was performed. The intensity of white
light represents the amount of nanoparticle in the cells
(Figure 4C). As anticipated, RGD@siRNA@HAuNstreated cells exhibited the strongest light signal in
cells compared to the weakest and low signals found
in free HAuNs- and siRNA@HAuNs-incubated cells.
This result confirmed that siRNA coating could
enhance the cell uptake of the nanoparticles and that
the RGD peptide conjugation can further improve the
cell targeting capability of siRNA@HAuNs. Further,
inductively coupled plasma-mass spectrometry
(ICP-MS) was applied to quantitatively determine the
elemental gold content in the H2228 cells (Figure 4D).
The intracellular content of Au was 3×104/per cell for
HAuNs incubation, 1×105/per cell for siRNA@
HAuNs-treated cells and 6×105/per cell for RGD@
siRNA@HAuNs-treated cells. The quantitative ICPMS results were consistent with the results of dark
field microscopy, further validating the enhanced
targeting efficiency provided by the RGD peptide.
To investigate the bio-distribution and
tumor-targeting ability of RGD@DOX@siRNA@
HAuNs in vivo, near-infrared fluorescence imaging
was performed in H2228 tumor-bearing nude mice.
MPA, a hydrophilic near-infrared fluorescence dye
with similar molecular weight as DOX, was used to
replace the DOX for NIR imaging. We found that
RDG@MPA@siRNA@HAuNs distributed throughout
the body within 30 min, then gradually accumulated
in the tumor site up to 12 h post-injection (Figure 4E).
As expected, no fluorescence signal was observed at
the tumor site in the MPA administration group. The
result demonstrated the favorable tumor-targeting
ability of the nanoshell-based drug carrier system. For
exploring the blood perfusion of tumor tissues upon
photothermal stimulation, the H2228 tumor bearing
mice with different treatments were sacrificed and the
tumor sections were analyzed by hematoxylin and
eosin (H&E) staining (Figure 4F). The blood perfusion
and extravasation were elevated upon laser
irradiation of the gold nanoshells, confirming the
enhanced blood permeability via thermal effects. In
contrast, less blood signal was observed in the group
without laser exposure. The data suggest that
additional antitumor drug will be effectively
delivered to the cancerous tissue through the blood
stream after NIR irradiation. To further investigate
the tumor delivery abilities, histological sections of
different organs (tumor, heart, liver, spleen, and
kidney) were analyzed by confocal microscopy. As
seen in Figure 4G, free DOX distributed in all the
http://www.thno.org
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Figure 4. The tumor-targeting ability of the RGD@siRNA@DOX@HAuNs drug carrier system. (A) Laser confocal microscopy images of the
cell-uptake ability of the nano-carrier with or without RGD modification; green: siRNA-FITC, blue: Hoechst. (B) The quantification of the laser confocal microscopy
images in (A). (C) Dark field microscopy images of H2228 cells with HAuNs, siRNA@HAuNs and RGD@siRNA@HAuNs incubation. (D) ICP-MS assay of HAuNs,
siRNA@HAuNs and RGD@siRNA@HAuNs in H2228 cells. (E) NIR images of MPA and RGD@siRNA@MPA@HAuNs dynamics in H2228 tumor-bearing nude
mice at different times after intravenous injection. (F) H&E stained sections of H2228 tumors after RGD@siRNA@MPA@HAuNs treatment and laser irradiation;
Laser-: treatments without NIR laser irradiation; Laser+: treatments with NIR laser irradiation. (G) Laser confocal microscopy images of tissue samples of tumor,
heart, liver, spleen and kidney from different treatment groups; red: fluoresce of DOX. Data are given as mean ± SD (n=5). *, P<0.05.

organs, indicating the potential for severe toxicity to
normal organs. For mice administrated with the
RGD-modified nanoshell system, strong DOX signal
was observed in the tumor tissue, while low signals
were exhibited in other tissues. These results show
that the RGD@DOX@siRNA@HAuNs have high
affinity to tumor tissue. Moreover, the tumor
accumulation of DOX was greatly improved by the
laser
irradiation,
confirming
the
enhanced
permeability of the tumor blood vessels by the
photothermal effect and reduced accumulation of
nano-drugs in other vital organs.

In vitro therapy of RGD@DOX@siRNA@
HAuNs
To investigate the cell toxicity of the HAuN
itself, a range of concentrations of HAuNs was
cultured with H2228 (Figure 5A). The results showed
that the H2228 tumor cells and L02 normal cells did
not exhibit obvious cytotoxicity until the

concentration of HAuNs exceeded 1.5 nM, which was
used in further studies.
The laser duration (illumination time) is an
important factor for this treatment. To identify the
optimal treatment time, different illumination time
gradients were tested with RGD@DOX@siRNA@
HAuNs, and the HAuNs were used as control group.
The results revealed that within 5 min irradiation, the
cell survival rate of the two groups were 23% and 47%
(Figure 5B) (p<0.05). Interestingly, beyond 5 min
irradiation, there was no obvious additional impact
on the cell survival. Thus, 5 min was the optimal time
for the therapy. Equally important, the treatment
effect of the RGD@DOX@siRNA@HAuNs group was
obviously better than that of the HAuNs group after
laser irradiation (cell survival rate less than double
reduce, p<0.05).
The therapeutic efficacies between single
treatment and combined treatment were also
http://www.thno.org
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compared in our study (Figure 5C). Using an in vitro
model, we found that the cell survival rate of each
group was 42% (HAuNs+Laser), 36.5%(DOX), and
20% (RGD@DOX@siRNA@HAuNs). These results
confirmed our hypothesis that the combined group
(compared with the single treatment: photothermal
induced by HAuNs, DOX, siRNA effect in figure 1C)
displayed the best treatment effect through a
multidimensional cooperative treatment effect that
includes hyperthermia, chemotherapy, and gene
therapy.
The ability of drug carriers to induce cell
apoptosis was also evaluated using a AV-PI kit
(Figure 5D). Flow cytometry results showed that the
apoptosis rate of the RGD@DOX@siRNA@HAuNs
group reached 69.1%, while that of the HAuNs group
was only 0.267%. Further, confocal microscopy
(Figure 5D) revealed that most cells were already in
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the late stage of apoptosis (red and green colors
represent the cells in the stage of apoptosis) after
treatment by RGD@DOX@siRNA@HAuNs + Laser,
indicating the excellent therapeutic efficacy of
RGD@DOX@siRNA@HAuNs at the cellular level. The
cell apoptosis rates caused by each monotherapy
(only ALK siRNA or only micRNA-301 inhibitor)
were less than the designed final drug system (Figure
S3).
Using Calcein-AV and PI to stain live and dead
cells, respectively, we show that most of the cells
treated with laser or HAuNs were not damaged
(Figure 5E). In contrast, the cells within the semicircle
dashed line (Figure 5Ed) were almost dead under the
HAuNs and laser treatment, while cells in the
unexposed area outside the semicircle were still alive.
This confirmed the role of HAuNs hyperthermia in
inducing apoptosis.

Figure 5. Treatment efficacy of RGD@siRNA@MPA@HAuNs at a cellular level. (A) Survival rate of H2228 cells and L02 cells after incubating with
different concentrations of bare HAuNs. (B) Survival rate of H2228 cells after incubating with bare HAuNs and RGD@siRNA@MPA@HAuNs with different laser
duration times. (C) Survival rate of H2228 cells treated under the above conditions determined by MTT assay. (D) Flow cytometry and laser confocal microscopy
examination of the apoptosis of H2228 cells after irradiation of RGD@siRNA@MPA@HAuNs. (E) Laser confocal microscopy of photothermal therapy of HAuNs
in H2228 cells; viable cells were stained green with Calcein-AV, and dead cells were stained red with PI. Cells were treated with only the dye (a) as the control group,
HAuNs without irradiation (b), irradiation only (c) and HAuNs with irradiation (d). Data are given as mean ± SD (n=5). *, P<0.05.
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In vivo antitumor therapeutic efficacy of
RGD@DOX@siRNA@HAuNs
The in vivo antitumor efficacy of RGD@DOX@
siRNA@HAuNs was further evaluated in a nude
mouse model (H2228 cells subcutaneous transplantation tumor). The tumor growth rate, survival rate
and the body weight of the mice under different
treatments were monitored (Figure 6). Tumors in the
control mice treated with saline grew faster than the
treated groups (Figure 6A-C). The RGD@DOX@
siRNA@HAuNs treatment group exhibited the
optimal inhibition effect of tumor growth. The growth
of H2228 tumor was inhibited at a rate of 65% after the
administration of RGD@DOX@siRNA@HAuNs+
laser, which is higher than that of the free HAuNs +
laser (43%) and free DOX (45%) groups. Furthermore,
the weight of mice bearing H2228 tumors in the
RGD@DOX@siRNA@HAuNs group was stable
compared with the DOX- and HAuNs-treated groups
(Figure 6D). The 22-day survival rate of mice in the
RGD@DOX@siRNA@HAuNs group was 80%, a much
better outcome than the free HAuNs (40%) and free
DOX (40%) groups, whereas all the mice in the saline
group died by day 16 (Figure 6E). These results
demonstrate the efficacy of multimodal nanoparticle
over the over the free DOX and photothermal (free
gold nanoshell) was realized by the RGD@DOX@
siRNA@HAuNs drug carrier system.
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To further investigate toxicity on the major
organs of mice and the anti-tumor effects of the
different treatments, histological examination was
conducted. The results showed that the number of
tumor cells in the saline-injected group was
significantly higher than that in the other two groups
(Figure 6F). The tumor cells were in a dense mitotic
condition, suggesting that the tumor cells were
primed for continued rapid proliferation. Histopathological examination of tumor tissues in the
RGD@DOX@siRNA@HAuNs-treated group revealed
more pronounced pathological changes than that of
the DOX-treated group. Clearly, the tumor treatment
efficacy of RGD@DOX@siRNA@HAuNs is superior to
that of free DOX in this study. Meanwhile, the
DOX-injected group showed more severe cardiotoxicity, liver toxicity and renal toxicity. In contrast,
the organ toxicity in the RGD@DOX@siRN @HAuNs
group was mild. The reason for this observation can
be attributed to the tumor-targeting drug carrier
system that efficiently delivered and retained more
drugs (DOX and siRNA) in the tumor tissue in vivo,
thereby enhancing the treatment efficacy with
minimal side effects. Finally, the ALK and Bim
expressions in the tumor tissue (RGD@DOX@
siRNA@HAuNs) were tested, and the results
exhibited that the expressions of ALK and Bim could
be inhibited effectively (Figure S4).

Figure 6. Antitumor therapeutic efficacy of RGD@DOX@siRNA@HAuNs on tumor-bearing mice. (A) Images of mice with tumors treated as
indicated. (B) Tumor volumes of mice bearing H2228 tumors under different treatments as indicated. (C) Tumor weights of mice bearing H2228 tumors from the
different treatment groups on the 16th day after injection. (D) Body weights of mice bearing H2228 tumors in the different groups. (E) The 16-day survival rates of
mice after different administrations. F, Analysis of the experiment tumor bearing mice tissue. A, H&E stained images of tumor, heart, liver, spleen and kidney sections
collected from different treatment groups. Data are given as mean ± SD (n=5). *, P<0.05.
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Conclusion
In this study, we designed and developed a
drug carrier system RGD@DOX@siRNA@HAuNs
targeted specifically for the treatment of EML4-ALK
gene fusion NSCLC. The multiple impressive qualities
of the new multidimensional nanoplatform includes
the high drug loading rate, controlled drug release,
and selective tumor targeting. The combination of
gene therapy, chemotherapy and thermal therapy
(siRNA, DOX, photothermal induced by free gold
nanoshell) exhibited a cooperative effect that
improved the treatment of EML4-ALK gene fusion
NSCLC in vitro and in vivo. This study provides a
promising strategy for the treatment EML4-ALK gene
fusion NSCLC.
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